How Psychiatric Labels Delay Perimenopause Diagnosis and What to Do Next

Perimenopause can be mistaken for primary anxiety or depression because mood changes, poor sleep, fatigue, and difficulty concentrating appear on psychiatric screening tools as well as during hormonal transition. A psychiatric label becomes a barrier when it prevents fuller assessment of possible hormonal contributions. Redirecting care means asking how perimenopause has been considered, what testing can establish, and when the treatment plan will be revisited.

Why women in perimenopause keep getting psychiatric diagnoses instead of hormonal ones

A woman talks about her anxiety, disrupted sleep, and mood instability. She completes a screening questionnaire, receives an SSRI prescription, and leaves with a follow-up in six weeks. Yet what has the encounter established about the cause? The PHQ-9 and similar depression screeners include sleep disruption, fatigue, difficulty concentrating, and mood disturbance, all of which can occur during perimenopause. A score can register distress without distinguishing hormonal contributions from a primary psychiatric disorder.

That distinction is where the category error begins. Symptoms described in psychiatric language are treated as evidence of a psychiatric cause before hormonal transition has been considered. Biote’s “Perimenopause Focus” survey found that a majority of women had received treatment for depression, anxiety, mood swings, or panic attacks since entering perimenopause. Nearly two in five of those women believed they were not appropriately diagnosed. More than half of respondents said their healthcare professional never suggested hormone blood testing, while a third of those tested reported no meaningful discussion of the results.

The Royal College of Psychiatrists raised concerns about this diagnostic overlap in March 2026, publishing its first-ever position statement on menopause and mental health. The statement warned that perimenopause symptoms are frequently misattributed to primary psychiatric disorders and called for improved clinical awareness. It also reported that three in four women did not know menopause could trigger a new mental health condition. Neither a screening score nor an unfamiliar patient can reliably prompt the conversation that the encounter needs.

How estrogen's reach into the brain makes hormonal symptoms look psychiatric

Estrogen’s role extends well beyond the reproductive system. It regulates thermoregulation, sleep, circadian rhythms, sensory processing, and several aspects of cognition. When its activity becomes erratic, the resulting symptoms can be neurological in origin yet sound psychiatric during a consultation. Poor concentration and disturbed sleep are not clues to only one diagnosis.

Perimenopause is also not simply a steady loss of estrogen. Its defining feature is volatility, which differs from the estrogen deficiency of menopause itself. The brain responds to variability as well as level. As ovarian function declines, the hypothalamic-pituitary-ovarian axis becomes dysregulated. Reduced ovarian production of inhibin B can accompany higher FSH and estradiol at the start of the cycle, while progesterone falls in the luteal phase. These shifts offer a neuroendocrine explanation for symptoms that a mood questionnaire can record but cannot explain.

How far can population evidence take that explanation? In their 2025 study in BMC Women’s Health, Ying Zhang and colleagues found that the disability-adjusted life year rate for perimenopausal anxiety rose between 1990 and 2021. Using the Global Burden of Disease database, the study projected a continued increase through 2035, reaching 1,180.43 per 100,000. That establishes a substantial burden while leaving hormonal causation in individual cases unresolved.

Women in the transition also face a substantially elevated risk of major depression, so hormonal and psychiatric explanations need not be mutually exclusive. Among women with affective symptoms, most report irritability as their main distress rather than the low mood that anchors standard depression criteria. The label may therefore miss both the trigger and the experience.

What happens to women who stay in the wrong treatment track

A treatment plan can treat the symptoms on record while leaving their cause unexplored. Olivia Hendriks and colleagues’ 2025 qualitative study in Women’s Health examined the experiences of 42 women with mental health struggles during perimenopause and menopause. Participants described worsening symptoms during delays in appropriate HRT and after misdiagnoses, including receiving antidepressants while HRT was delayed. Only a minority of those prescribed antidepressants reported benefit. Most reported no improvement.

A qualitative study documents experience rather than proving that antidepressants cannot help hormonally influenced symptoms. Its finding is narrower and still consequential. For these participants, the first treatment often did not help, while those who received timely HRT reported improvements in mental well-being. Their experiences show why persistent symptoms should prompt reconsideration of the diagnosis.

The same study documented suicidality ranging from abstract thoughts to suicide attempts, which most affected participants had not experienced before perimenopause. This documents the severity experienced by affected participants. It also does not make psychiatric care irrelevant. Rather, it shows why serious mental health symptoms and possible hormonal contributors both deserve attention.

Biote’s survey found a further gap before treatment choice even arose. Nearly half of women experiencing perimenopause symptoms said they had never been offered treatment for them. Among those dissatisfied with provider interactions, a majority felt their concerns were not fully addressed, and a substantial share said their providers did not take them seriously. An unsuccessful prescription was compounded by an encounter in which the account of distress failed to receive adequate consideration.

Why clinicians reach for the wrong tool — and what they are working with instead

Jo Burgin and colleagues’ 2025 qualitative study in the British Journal of General Practice found that GPs varied in how they asked about perimenopausal symptoms and acknowledged gaps in their training. They also described time constraints and stigma as barriers to assessment. These are practical limits. Yet they leave clinicians less equipped to distinguish overlapping presentations.

The patient side of the consultation compounds those limits. The same study found that women either did not know perimenopause could contribute to their mental health symptoms or felt uncertain and inhibited about raising it. Each side can therefore wait for the other to introduce the possibility. Biote’s survey found that only 42% of women said their primary care provider or OB/GYN had initiated discussions about perimenopause symptoms during regular appointments. For the majority, proactive guidance was missing.

A psychiatric screener offers a clear route through that uncertainty. It provides a validated instrument and a scoring threshold within a time-limited appointment, whereas distinguishing overlapping causes requires a broader conversation. Efficiency does not establish diagnostic completeness. A woman may move quickly into psychiatric treatment because that pathway is readily available, while hormonal contributions have yet to be ruled out. Interrupting that default requires room for a different question within the consultation.

Why hormone testing is harder to interpret than it looks — and why that matters for what you ask for

That different question is not necessarily answered by a blood draw. The European Society of Endocrinology recommends that biochemical testing is unnecessary for diagnosing or managing perimenopause or menopause in women older than 45 years. A clinician can therefore decline testing without dismissing perimenopause.

Testing requires more careful consideration in younger women and in presentations dominated by psychiatric-seeming symptoms. Even then, a single FSH result is not a diagnosis. FSH fluctuates during perimenopause and can return to premenopausal levels after an elevated reading. A normal result in a symptomatic woman in her early 40s does not, by itself, exclude perimenopause. A single elevated reading also cannot explain the whole clinical picture.

Timing changes what a result can tell you. The Society recommends measuring FSH on days 2–5 of the menstrual cycle or after more than 40 days without menstruation. Day three gives the most consistent results when cycles are still regular. Progesterone answers a different timing question and needs measurement in the mid-luteal phase, roughly a week after ovulation. That is typically around day 21 of a 28-day cycle, with the appointment date adjusted for each person’s actual cycle length.

The Swiss Perimenopause Study investigated steroid hormone fluctuations by following participants over 13 months, building on earlier studies that had reported increases in estradiol. Its longitudinal approach reflects the difficulty of interpreting a moving process from one snapshot. Hormonal investigation needs a clinical purpose and a plan for interpreting results.

How to redirect your care when the clinical encounter is pulling toward psychiatry

The lesson for an appointment is to name the hormonal possibility explicitly. Ask whether perimenopause could play a part in the anxiety, sleep disruption, irritability, or cognitive changes being assessed. Then ask how the clinician will distinguish that contribution from a primary mood disorder. Burgin’s study identified uncertainty and inhibition as barriers, so raising the question directly addresses a documented point of failure.

To make that conversation more concrete, document symptoms over time before the appointment. Write down mood shifts, how well you sleep, any cycle irregularity, and cognitive symptoms. A pattern across weeks can show the clinician how the experience changes over time. The record supports assessment without asking you to diagnose yourself.

If testing is being considered, ask about a timed, comprehensive panel to check “hormone levels. The discussion can include estradiol, progesterone, FSH, LH, and testosterone, with an explanation of what each would contribute. Ask specifically about mid-luteal timing for progesterone and days 2–5 for FSH. These measurements do not all belong at the same point in the cycle. Given the limits of routine testing, the request should also establish why each test is appropriate and how the results will inform care.

Training is another reasonable subject to raise. Ask what formal menopause training is available within the practice and, if that expertise is absent, request referral to a clinician who has it. A referral can be a way to fill a knowledge gap.

If psychiatric treatment is offered first, ask what the plan is for assessing hormonal contributions and what would trigger reconsideration. If symptoms persist, would that lead to a broader assessment? How will the symptom record and any test results be reviewed? The purpose is to keep follow-up diagnostically open. An SSRI prescription should not become the unspoken conclusion of the hormonal discussion.

What the right diagnosis actually opens up for treatment

Recognizing a hormonal contribution makes HRT a treatment option to assess. Hendriks’ study documented women’s reported improvements in mental well-being after timely HRT, in contrast with the limited benefit many described from antidepressants. That contrast supports closer attention to treatment fit. It does not show that every woman with anxiety or depression during perimenopause needs HRT, or that hormonal treatment can replace all mental health care.

An accurate diagnosis can also clarify non-hormonal options. Cognitive behavioral therapy has documented benefit for reducing hot flashes, night sweats, and anxiety in the perimenopausal context. Co-occurring conditions require similar precision. When estrogen loss unmasks a co-occurring neurodevelopmental condition, for example, identifying hormonal change allows both conditions to be addressed rather than forcing the symptoms into a single explanation.

Follow-up remains important because the transition is not static. Hormonal fluctuations continue, and treatment response varies, so tracking after treatment begins can help inform whether the approach is working or needs adjustment. Where hormone measurements are clinically useful, longitudinal data interpreted by a clinician can add context that a baseline test lacks. A home testing and clinician review model offers that possibility, but its value rests on meaningful timing and interpretation.

The goal is care that can respond as the evidence changes. That means keeping both psychiatric and hormonal causes in mind, without assuming either explains every symptom, until there is enough evidence to choose treatment that fits.